Investigational drugs in phase I and phase II clinical trials for the treatment of community-acquired pneumonia

Keyphrases

• Antibiotic Resistance 100%
• Community-acquired Pneumonia 100%
• Phase III Clinical Trial 100%
• Investigational Drugs 100%
• Phase II Clinical Trial 100%
• Expert Opinion 50%
• Treatment Options 50%
• Multidrug-resistant Bacteria 50%
• Pneumonia 50%
• Successful Treatment 50%
• Disease Severity 50%
• Spectrum of Activity 50%
• International Guidelines 50%
• Area Cover 50%
• Quinolones 50%
• New Antibiotics 50%
• Macrolides 50%
• Antibiotic Class 50%
• Lactams 50%
• Appropriate Antibiotic Therapy 50%
• Tetracycline 50%
• Pharmaceutical Companies 50%
• Oxazolidinone 50%
• Novel Antibiotics 50%
• Actual Situation 50%
• Clinical Placement 50%
• Rapid Advancement 50%
• New Antibacterials 50%
• Current Treatment 50%
• Medical Significance 50%
• Cyclic Peptide 50%
• Narrow Spectrum 50%
• Outpatient Antibiotics 50%
• Lipoglycopeptide 50%
• Antibacterial Agents 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Antibiotics 100%
• Clinical Trial 100%
• Community Acquired Pneumonia 100%
• Investigational Drug 100%
• Antibiotic Resistance 100%
• Infection 50%
• Infectious Agent 50%
• Antiinfective Agent 50%
• Antibiotic Therapy 50%
• Macrolide 50%
• Quinolone Derivative 50%
• Lactam 50%
• Lipopeptide 50%
• Oxazolidinone Derivative 50%
• Tetracycline Derivative 50%
• Diseases 50%